Millennium Biotechnologies, Inc. Announces Emerging New Data On Their Exclusive Ingredient SOD/Gliadin -DefenZyme-.

Business Editors/Health/Medical Writers

BASKING RIDGE, N.J.--(BUSINESS WIRE)--May 13, 2004

Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB: MBTG) is pleased to announce that a study utilizing SOD/gliadin (DefenZyme(TM) was accepted for publication by the Journal of Ethnopharmacology. Millennium has an exclusive license for the use of SOD/Glidain in the medical markets and is a key ingredient in both of the Company's flagship products Resurgex(R) and Resurgex Plus(TM). The study titled "Anti-oxidant and anti-inflammatory properties of a Cucumis melo extract rich in superoxide dismutase activity (SOD/Gliadin)" confirms the clinically important role that SOD/gliadin plays as a nutraceutical ingredient. SOD/gliadin represents the first orally effective, vegetarian form of the body's most important antioxidant defense enzyme called superoxide dismutase (SOD) and is a critical ingredient in Millennium's proprietary products Resurgex(R), Resurgex Plus(TM) and DefenZyme(TM).

"This is only one of over 20 scientific papers that have been submitted for publication on the importance of SOD/gliadin" states Carl Germano, RD, CNS, CDN, Vice President of Research & Product Development. "This orally effective form of superoxide dismutase represents one of the most important, clinically relevant nutritional agents to come to market in decades. While the data has been established on the role of SOD as an antioxidant that can also lower inflammatory messengers, SOD/gliadin is the only orally effective form to demonstrate additional beneficial roles in the body. In addition to the important in-vitro and animal studies on SOD/gliadin, human data now exists and has been submitted for publication on the role of SOD/gliadin lowering lactic acid, reducing oxidative stress and upregulating total antioxidant defenses."

This emerging new data supports the rationale and inclusion of SOD/gliadin to Millennium's flagship products Resurgex(R), Resurgex Plus(TM) and Defenzyme(TM) as well as in their newly developed nutritional products aimed at supporting those with osteoporosis and diabetes. These products represent another milestone for the company and its goal to provide effective nutritional support, above and beyond the traditional fat and sugar based products, as a meaningful nutritional adjunct to medial care.

Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies, Group, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized enteral nutritional formulas and nutraceuticals. The company's first two products, Resurgex(R) and Resurgex Plus(TM), are the first multiple action nutritional formulas designed to assist in increasing energy, maintaining lean muscle, reducing oxidative stress and supporting immune function in patients with HIV/AIDS, Hepatitis C, cancer or other chronic illnesses as an adjunct to their medical care. Both Resurgex(R) and Resurgex Plus(TM), contain the critically important, orally effective form of SOD (GliSODin(R)) along with several other important nutritional components. These products are being reimbursed by Medicaid in certain states, and the company plans to launch in other targeted locales upon further qualifications. For more information about Millennium Biotechnologies, Inc., log onto www.milbiotech.com.

This news release contains forward-looking statements that are based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.